MARKET

DVAX

DVAX

Dynavax Techs
NASDAQ

Real-time Quotes | Nasdaq Last Sale

6.03
-0.14
-2.27%
After Hours: 6.08 +0.05 +0.83% 19:59 01/17 EST
OPEN
6.27
PREV CLOSE
6.17
HIGH
6.36
LOW
6.01
VOLUME
1.07M
TURNOVER
--
52 WEEK HIGH
12.29
52 WEEK LOW
2.595
MARKET CAP
505.71M
P/E (TTM)
-2.5076
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of DVAX and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

DVAX News

  • Dynavax Technologies Option Alert: Feb 21 $7 Calls Sweep (15) near the Ask: 535 @ $0.55 vs 231 OI; Earnings 2/25 After Close [est] Ref=$6.09
  • Benzinga.1d ago
  • Why Dynavax Technologies Corporation Stock Cratered in 2019
  • MotleyFool.com.1d ago
  • Dynavax: Concentrating On Vaccines Could Stabilize The Investment
  • Seeking Alpha - Article.12/30/2019 21:29
  • The Daily Biotech Pulse: Roche Gets US Antitrust Clearance For Spark Purchase, An Orphan Drug Designation For Prevail, Dynavax Names CEO
  • Benzinga.12/17/2019 12:56

More

Industry

Biotechnology & Medical Research
-0.10%
Pharmaceuticals & Medical Research
+0.07%

Hot Stocks

Name
Price
%Change

About DVAX

Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma. Its products include HEPLISAV-B, AZD1419, SD-101, DV281, DV230F and DV1001. HEPLISAV-B is an investigational adult hepatitis B vaccine. AZD1419 is being developed for the treatment of asthma. SD-101 is an investigational TLR9 agonist designed to elicit a potent and focused immune response to cancer. DV281 is an investigational TLR9 agonist designed specifically for focused delivery to primary lung tumors and lung metastases. DV230F is indicated for the treatment of Liver Tumors. DV1001 targets TLR 7 and 8 agonist for multiple malignancies. DV230F and DV1001 are in pre-clinical stage of development.
More

Webull offers Dynavax Technologies Corporation (DVAX) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.